Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.71 USD | -0.88% | -2.78% | +115.69% |
Business Summary
Number of employees: 100
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Antibody-based Therapeutic Products
100.0
%
| 49 | 100.0 % | 84 | 100.0 % | +71.15% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
80.4
%
| 46 | 93.9 % | 68 | 80.4 % | +46.60% |
Other Countries
19.6
%
| 3 | 6.1 % | 17 | 19.6 % | +448.70% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Thomas Gad
FOU | Founder | 54 | 15-03-31 |
Michael Rossi
CEO | Chief Executive Officer | 53 | 11-05 |
Bo Kruse
DFI | Director of Finance/CFO | 52 | 16-05-31 |
Vignesh Rajah
CTO | Chief Tech/Sci/R&D Officer | 59 | 20-05-31 |
Joris Wilms
COO | Chief Operating Officer | 50 | 17-10-31 |
Chief Tech/Sci/R&D Officer | 73 | 15-12-31 | |
Sue Smith
PRN | Corporate Officer/Principal | 54 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Gill
BRD | Director/Board Member | 69 | 17-11-30 |
Director/Board Member | 54 | 15-08-31 | |
James Healy
CHM | Chairman | 58 | 17-10-31 |
Ashutosh Tyagi
BRD | Director/Board Member | 47 | 17-10-31 |
Bo Kruse
DFI | Director of Finance/CFO | 52 | 16-05-31 |
Gérard Ber
BRD | Director/Board Member | 66 | 18-12-10 |
Michael Rossi
CEO | Chief Executive Officer | 53 | 11-05 |
Thomas Gad
FOU | Founder | 54 | 15-03-31 |
Laura Hamill
BRD | Director/Board Member | 60 | 20-03-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 43,777,105 | 37,409,819 ( 85.46 %) | 0 | 85.46 % |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+115.69% | 644M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- YMAB Stock
- Company Y-mAbs Therapeutics, Inc.